Skip to main content
SpringerLink
Log in

Co-occurring Disorders

  • Chapter
  • First Online:
Diversity in Action

  • 331 Accesses

Abstract

Co-occurring disorders are prevalent across multiple cultural contexts affecting individuals of varying socioeconomic, racial, and occupational backgrounds, often with devastating consequences. Individuals with substance use disorders and mental illness have an increased risk of suicide and adverse events, frequently made worse by higher rates of leaving hospitals against medical advice. Unfortunately, healthcare systems across the world have difficulty effectively treating patients with co-occurring disorders due to social and systemic barriers. Public policy interventions and multifactorial internal reform are needed to better engage this population.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. Key substance use and mental health indicators in the United States: results from the 2019 National Survey on Drug Use and Health. 2019.

    Google Scholar 

  2. Degenhardt L, Whiteford HA, Ferrari AJ, Baxter AJ, Charlson FJ, Hall WD, Freedman G, Burstein R, Johns N, Engell RE, Flaxman A. Global burden of disease attributable to illicit drug use and dependence: findings from the Global Burden of Disease Study 2010. Lancet. 2013;382(9904):1564–74.

    Article  PubMed  Google Scholar 

  3. Ti L, Ti L. Leaving the hospital against medical advice among people who use illicit drugs: a systematic review. Am J Public Health. 2015;105(12):2587.

    Article  PubMed Central  Google Scholar 

  4. Tan SY, Feng JY, Joyce C, Fisher J, Mostaghimi A. Association of hospital discharge against medical advice with readmission and in-hospital mortality. JAMA Netw Open. 2020;3(6):e206009.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Green AI, Drake RE, Brunette MF, Noordsy DL. Schizophrenia and co-occurring substance use disorder. Am J Psychiatry. 2007;164(3):402–8. https://doi.org/10.1176/ajp.2007.164.3.402. PMID: 17329463

    Article  PubMed  Google Scholar 

  6. Brunette MF, Noordsy DL, Xie H, Drake RE. Benzodiazepine use and abuse among patients with severe mental illness and co-occurring substance use disorders. Psychiatr Serv. 2003;54(10):1395–401. https://doi.org/10.1176/appi.ps.54.10.1395. PMID: 14557527

    Article  PubMed  Google Scholar 

  7. Avery JD, Avery JJ, editors. The stigma of addiction: an essential guide. Springer; 2019.

    Google Scholar 

  8. National Institute on Drug Abuse. Trends & Statistics. 2017.

    Google Scholar 

  9. Ali MM, Teich JL, Mutter R. The role of perceived need and health insurance in substance use treatment: implications for the Affordable Care Act. J Subst Abus Treat. 2015;54:14–20.

    Article  Google Scholar 

  10. Mojtabai R, Mauro C, Wall MM, Barry CL, Olfson M. Private health insurance coverage of drug use disorder treatment: 2005–2018. PLoS One. 2020;15(10):e0240298.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Mark TL, Yee T, Levit KR, Camacho-Cook J, Cutler E, Carroll CD. Insurance financing increased for mental health conditions but not for substance use disorders, 1986–2014. Health Aff. 2016;35(6):958–65.

    Article  Google Scholar 

  12. Tsai AC, Kiang MV, Barnett ML, Beletsky L, Keyes KM, McGinty EE, Smith LR, Strathdee SA, Wakeman SE, Venkataramani AS. Stigma as a fundamental hindrance to the United States opioid overdose crisis response. PLoS Med. 2019;16(11):e1002969.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Yates K, Lång U, Cederlöf M, Boland F, Taylor P, Cannon M, McNicholas F, DeVylder J, Kelleher I. Association of psychotic experiences with subsequent risk of suicidal ideation, suicide attempts, and suicide deaths: a systematic review and meta-analysis of longitudinal population studies. JAMA Psychiat. 2019;76(2):180–9.

    Article  Google Scholar 

  14. Hatzenbuehler ML, Keyes KM, Narrow WE, Grant BF, Hasin DS. Racial/ethnic disparities in service utilization for individuals with co-occurring mental health and substance use disorders in the general population. J Clin Psychiatry. 2008;69(7):1112.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Anderson P, Baumberg B. Alcohol in Europe, vol. 2. London: Institute of Alcohol Studies; 2006. p. 73–5.

    Google Scholar 

  16. Miron JA, Zwiebel J. Alcohol consumption during prohibition. National Bureau of Economic Research; 1991.

    Book  Google Scholar 

  17. Levine HG. The Committee of Fifty and the origins of alcohol control. J Drug Issues. 1983;13(1):95–116.

    Article  Google Scholar 

  18. Kurtz E. Alcoholics anonymous and the disease concept of alcoholism. Alcohol Treat Q. 2002;20(3–4):5–39.

    Article  Google Scholar 

  19. White AM, Castle IJP, Hingson RW, Powell PA. Using death certificates to explore changes in alcohol-related mortality in the United States, 1999 to 2017. Alcohol Clin Exp Res. 2020;44(1):178–87.

    Article  PubMed  Google Scholar 

  20. Metrebian N. Influences on the prescribing of heroin for the treatment of opiate dependence in the United Kingdom. London: University of London; 2005.

    Google Scholar 

  21. Strang J, Groshkova T, Metrebian N. European Monitoring Centre for Drugs and Drug Addiction. New heroin-assisted treatment: recent evidence and current practices of supervised injectable heroin treatment in Europe and beyond. Luxembourg: Publications Office of the European Union; 2012.

    Google Scholar 

  22. Perneger T, Giner F, del Rio M, Mino A. Randomized trial of heroin maintenance programme for addicts who fail in conventional drug treatment. BMJ. 1998;317(7150):13–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Jiang R, Lee I, Lee TA, Pickard AS. The societal cost of heroin use disorder in the United States. PLoS One. 2017;12(5):e0177323.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Weinmeyer R. Needle exchange programs’ status in US politics. AMA J Ethics. 2016;18(3):252–7.

    Article  PubMed  Google Scholar 

  25. Cohen A. How white users made heroin a public-health problem. The Atlantic. 2015.

    Google Scholar 

  26. Mack KA, Jones CM, Ballesteros MF. Illicit drug use, illicit drug use disorders, and drug overdose deaths in metropolitan and nonmetropolitan areas—United States. Am J Transplant. 2017;17(12):3241–52.

    Google Scholar 

  27. Peters DJ, Monnat SM, Hochstetler AL, Berg MT. The opioid hydra: understanding overdose mortality epidemics and syndemics across the rural-urban continuum. Rural Sociol. 2020;85(3):589–622.

    Article  PubMed  Google Scholar 

  28. Jones CM, Bekheet F, Park JN, Alexander GC. The evolving overdose epidemic: synthetic opioids and rising stimulant-related harms. Epidemiol Rev. 2020;42(1):154–66. https://doi.org/10.1093/epirev/mxaa011.

    Article  PubMed  Google Scholar 

  29. Mattson CL, Tanz LJ, Quinn K, Kariisa M, Patel P, Davis NL. Trends and geographic patterns in drug and synthetic opioid overdose deaths — United States, 2013–2019. MMWR Morb Mortal Wkly Rep. 2021;70:202–7. https://doi.org/10.15585/mmwr.mm7006a4.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Anderson AL, Li SH, Biswas K, McSherry F, Holmes T, Iturriaga E, Kahn R, Chiang N, Beresford T, Campbell J, Haning W. Modafinil for the treatment of methamphetamine dependence. Drug Alcohol Depend. 2012;120(1–3):135–41.

    Article  CAS  PubMed  Google Scholar 

  31. Substance Abuse and Mental Health Services Administration: Center for Behavioral Health Statistics and Quality. Key substance use and mental health indicators in the United States: results from the 2018 National Survey on Drug Use and Health (HHS Publication No. PEP19–5068, NSDUH series H-54). Rockville: Substance Abuse and Mental Health Services Administration; 2019.

    Google Scholar 

  32. Winkelman TN, Admon LK, Jennings L, Shippee ND, Richardson CR, Bart G. Evaluation of amphetamine related hospitalizations and associated clinical outcomes and costs in the United States. JAMA. 2018;1(6):e183758.

    Google Scholar 

  33. United States. Public Health Service. Office of the Surgeon General, National Center for Chronic Disease Prevention, & Health Promotion (US). Office on Smoking. Preventing tobacco use among young people: a report of the surgeon general, vol. Vol. 10. US Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 1994.

    Google Scholar 

  34. US Department of Health and Human Services. The health consequences of smoking—50 years of progress: a report of the surgeon general. Rockville: U.S. Department of Health and Human Services; 2014.

    Google Scholar 

  35. Substance Abuse and Mental Health Services Administration, National Mental Health Services Survey (N-MHSS): 2017. Data on Mental Health Treatment Facilities. BHSIS Series S-98, HHS Publication No. (SMA) 17-5049. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2018.

    Google Scholar 

  36. Maharajh HD, Abdool PS. Cultural aspects of suicide. TheScientificWorldJOURNAL. 2005;1:5.

    Google Scholar 

  37. Schmitt T. Stuff White People Like... To Keep: re-appropriation and whiteness in America. Augsburg Honors Rev. 2012;5(1):4.

    Google Scholar 

  38. United Nations Office on Drugs and Crime. World drug report 2020. 25 June 2020. https://wdr.unodc.org/wdr2020/index.html.

  39. Hser YI, Grella CE, Hubbard RL, et al. An evaluation of drug treatments for adolescents in 4 US cities. Arch Gen Psychiatry. 2001;58(7):689–695.

    Google Scholar 

  40. Dingle GA, Cruwys T, Frings D. Social identities as pathways into and out of addiction. Front Psychol. 2015.

    Google Scholar 

  41. Hussong AM, Ennett ST, McNeish D, Rothenberg WA, Cole V, Gottfredson NC, Faris RW. Teen social networks and depressive symptoms-substance use associations: developmental and demographic variation. J Stud Alcohol Drugs. 2018;79(5):770–80.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Copeland M, Fisher JC, Moody J, Feinberg ME. Different kinds of lonely: dimensions of isolation and substance use in adolescence. J Youth Adolesc. 2018;47(8):1755–70.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Fosnocht AQ, Lucerne KE, Ellis AS, Olimpo NA, Briand LA. Adolescent social isolation increases cocaine seeking in male and female mice. Behav Brain Res. 2019;359:589–96.

    Article  CAS  PubMed  Google Scholar 

  44. Rapier R, McKernan S, Stauffer CS. An inverse relationship between perceived social support and substance use frequency in socially stigmatized populations. Addict Behav Rep. 2019;10:100188.

    PubMed  PubMed Central  Google Scholar 

  45. Wilkens C, Foote J. “Bad Parents,”“Codependents,” and other stigmatizing myths about substance use disorder in the family. In: The stigma of addiction. Springer; 2019. p. 33–53.

    Chapter  Google Scholar 

  46. U.S. Department of Health and Human Services Final report: opioid use, misuse, and overdose in women. 2017.

    Google Scholar 

  47. American College of Obstetricians and Gynecologists (ACOG), American Society of Addiction Medicine (ASAM). Committee opinion: opioid abuse, dependence, and addiction in pregnancy, vol. 524. Committee on Health Care for Underserved Women and the American Society of Addiction Medicine; 2012. p. 1–7.

    Google Scholar 

  48. Substance Abuse and Mental Health Services Administration. SAMHSA’s Concept of Trauma and guidance for a traumainformed approach. 2014. https://store.samhsa.gov/system/files/sma14-4884.pdf

    Google Scholar 

  49. Embree JA. Prevalence of suicide attempts in a deaf population with co-occurring substance use disorder. JADARA. 2019;45(2):1–15.

    Google Scholar 

  50. Anderson ML, Chang BH, Kini N. Alcohol and drug use among deaf and hard-of-hearing individuals: a secondary analysis of NHANES 2013–2014. Subst Abus. 2018;39(3):390–7.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Moore D, Li L. Prevalence and risk factors of illicit drug use by people with disabilities. Am J Addict. 1998;7(2):93–102.

    Article  CAS  PubMed  Google Scholar 

  52. Peters RH, Bartoi MG, Sherman PB. Screening and assessment of co-occurring disorders in the justice system. Delmar: GAINS Center; 1997.

    Google Scholar 

  53. Gates ML, Turney A, Ferguson E, Walker V, Staples-Horne M. Associations among substance use, mental health disorders, and self-harm in a prison population: examining group risk for suicide attempt. Int J Environ Res Public Health. 2017;14(3):317.

    Article  PubMed Central  Google Scholar 

  54. Peters RH, Wexler HK, Lurigio AJ. Co-occurring substance use and mental disorders in the criminal justice system: a new frontier of clinical practice and research. Psychiatr Rehabil J. 2015;38:1–6.

    Article  PubMed  Google Scholar 

  55. Maguen S, Metzler TJ, Bosch J, Marmar CR, Knight SJ, Neylan TC. Killing in combat may be independently associated with suicidal ideation. Depress Anxiety. 2012;29(11):918–23.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Institute of Medicine. Substance use disorders in the US armed forces. Washington, DC: National Academies Press; 2013. https://www.nap.edu/catalog/13441/substance-use-disorders-in-the-us-armed-forces.

    Google Scholar 

  57. Dickerson DL, Spear S, Marinelli-Casey P, Rawson R, Li L, Hser YI. American Indians/Alaska natives and substance abuse treatment outcomes: positive signs and continuing challenges. J Addict Dis. 2010;30(1):63–74.

    Article  Google Scholar 

  58. Kranzler HR, Soyka M. Diagnosis and pharmacotherapy of alcohol use disorder: a review. JAMA. 2018;320(8):815–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Cain C. Personal stories: identity acquisition and self-understanding in alcoholics anonymous. Ethos. 1991;19(2):210–53.

    Article  Google Scholar 

  60. Kaskutas LA. Alcoholics anonymous effectiveness: faith meets science. J Addict Dis. 2009;28(2):145–57.

    Article  PubMed  PubMed Central  Google Scholar 

  61. Ferri M, Amato L, Davoli M. Alcoholics anonymous and other 12-step programmes for alcohol dependence. Cochrane Database Syst Rev. 2006;(3):CD005032.

    Google Scholar 

  62. Litten RZ, Wilford BB, Falk DE, Ryan ML, Fertig JB. Potential medications for the treatment of alcohol use disorder: an evaluation of clinical efficacy and safety. Subst Abus. 2016;37(2):286–98.

    Article  PubMed  Google Scholar 

  63. Reif S, George P, Braude L, Dougherty RH, Daniels AS, Ghose SS, Delphin-Rittmon ME. Residential treatment for individuals with substance use disorders: assessing the evidence. Psychiatr Serv. 2014;65(3):301–12.

    Article  PubMed  Google Scholar 

  64. Suter M, Strik W, Moggi F. Depressive symptoms as a predictor of alcohol relapse after residential treatment programs for alcohol use disorder. J Subst Abus Treat. 2011;41(3):225–32.

    Article  Google Scholar 

  65. Mason BJ. Emerging pharmacotherapies for alcohol use disorder. Neuropharmacology. 2017;122:244–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Burchi E, Makris N, Lee MR, Pallanti S, Hollander E. Compulsivity in alcohol use disorder and obsessive compulsive disorder: implications for neuromodulation. Front Behav Neurosci. 2019;13:70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Philip NS, Sorensen DO, McCalley DM, Hanlon CA. Non-invasive brain stimulation for alcohol use disorders: state of the art and future directions. Neurotherapeutics. 2020;17(1):116–26.

    Article  PubMed  Google Scholar 

  68. Fullerton CA, Kim M, Thomas CP, Lyman DR, Montejano LB, Dougherty RH, et al. Medication-assisted treatment with methadone: assessing the evidence. Psychiatr Serv. 2014;65(2):146–57.

    Article  PubMed  Google Scholar 

  69. Maglione MA, Raaen L, Chen C, Azhar G, Shahidinia N, Shen M, et al. Effects of medication assisted treatment (MAT) for opioid use disorder on functional outcomes: a systematic review. J Subst Abus Treat. 2018;89:28–51.

    Article  Google Scholar 

  70. Oesterle TS, Thusius NJ, Rummans TA, Gold MS. Medication-assisted treatment for opioid-use disorder. Mayo Clin Proc. 2019;94:2072–86. https://doi.org/10.1016/j.mayocp.2019.03.029.

    Article  PubMed  Google Scholar 

  71. Jones JL, Mateus CF, Malcolm RJ, Brady KT, Back SE. Efficacy of ketamine in the treatment of substance use disorders: a systematic review. Front Psych. 2018;9:277.

    Article  Google Scholar 

  72. Ezquerra-Romano II, Lawn W, Krupitsky E, Morgan CJ. Ketamine for the treatment of addiction: evidence and potential mechanisms. Neuropharmacology. 2018;142:72–82.

    Article  Google Scholar 

  73. Young JR, Smani SA, Mischel NA, Kritzer MD, Appelbaum LG, Patkar AA. Non-invasive brain stimulation modalities for the treatment and prevention of opioid use disorder: a systematic review of the literature. J Addict Dis. 2020;38(2):186–99.

    Article  PubMed  Google Scholar 

  74. Sawynok J. The therapeutic use of heroin: a review of the pharmacological literature. Can J Physiol Pharmacol. 1986;64(1):1–6. https://doi.org/10.1139/y86-001. PMID: 2420426

    Article  CAS  PubMed  Google Scholar 

  75. Fischer B, Oviedo-Joekes E, Blanken P, Haasen C, Rehm J, Schechter MT, Strang J, van den Brink W. Heroin-assisted treatment (HAT) a decade later: a brief update on science and politics. J Urban Health. 2007;84(4):552–62.

    Article  PubMed  PubMed Central  Google Scholar 

  76. Bernhardt N, Petzold J, Groß C, Scheck A, Pooseh S, Mayer-Pelinski R, Zimmermann US, Smolka MN, Pilhatsch M. Neurocognitive dysfunctions and their therapeutic modulation in patients with methamphetamine dependence: a pilot study. Front Psych. 2020;11:581.

    Article  Google Scholar 

  77. Zweben JE, Cohen JB, Christian D, Galloway GP, Salinardi M, Parent D, Iguchi M. Psychiatric symptoms in methamphetamine users. Am J Addict. 2004;13(2):181–90.

    Article  PubMed  Google Scholar 

  78. Longo M, Wickes W, Smout M, Harrison S, Cahill S, White JM. Randomized controlled trial of dexamphetamine maintenance for the treatment of methamphetamine dependence. Addiction. 2010;105(1):146–54.

    Article  PubMed  Google Scholar 

  79. Clark M, Featherstone R. Management of acute withdrawal and detoxification for adults who misuse methamphetamine: a review of the clinical evidence and guidelines. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2019.

    Google Scholar 

  80. Morley KC, Cornish JL, Faingold A, Wood K, Haber PS. Pharmacotherapeutic agents in the treatment of methamphetamine dependence. Expert Opin Investig Drugs. 2017;26(5):563–78.

    Article  CAS  PubMed  Google Scholar 

  81. Colfax GN, Santos GM, Das M, Santos DM, Matheson T, Gasper J, Shoptaw S, Vittinghoff E. Mirtazapine to reduce methamphetamine use: a randomized controlled trial. Arch Gen Psychiatry. 2011;68:1168–75.

    Article  PubMed  PubMed Central  Google Scholar 

  82. Chaiton M, Diemert L, Cohen JE, Bondy SJ, Selby P, Philipneri A, Schwartz R. Estimating the number of quit attempts it takes to quit smoking successfully in a longitudinal cohort of smokers. BMJ Open. 2016;6(6):e011045.

    Article  PubMed  PubMed Central  Google Scholar 

  83. Antonelli M, Fattore L, Sestito L, Di Giuda D, Diana M, Addolorato G. Transcranial magnetic stimulation: a review about its efficacy in the treatment of alcohol, tobacco and cocaine addiction. Addict Behav. 2021;114:106760.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry, University of California San Diego, San Diego, CA, USA

    Aaron Meyer, Gabriela G. Mejia & Hilary M. Gould

Authors
  1. Aaron Meyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gabriela G. Mejia
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hilary M. Gould
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Aaron Meyer .

Editor information

Editors and Affiliations

  1. Department of Psychiatry, University of California San Diego, San Diego, CA, USA

    Steve H. Koh

  2. Department of Psychiatry, University of California San Diego, San Diego, CA, USA

    Gabriela G. Mejia

  3. Department of Psychiatry, University of California San Diego, San Diego, CA, USA

    Hilary M. Gould

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Meyer, A., Mejia, G.G., Gould, H.M. (2022). Co-occurring Disorders. In: Koh, S.H., Mejia, G.G., Gould, H.M. (eds) Diversity in Action. Springer, Cham. https://doi.org/10.1007/978-3-030-85401-0_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-85401-0_5

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-85400-3

  • Online ISBN: 978-3-030-85401-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation